Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products
China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced its financial results for the...
Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed LM-24C5 has received clinical trial...
Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) reported another strong quarterly performance with...
Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales
US-based biopharma Amgen Inc. (NASDAQ: AMGN) released its Q2 2025 financial results, showing a 9%...
Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX
Guangdong China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main...
NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender
The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...
Neowise Biotechnology’s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy
China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy...
Dizal Pharma’s DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192) announced that its investigational product DZD8586 has been...
AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced the official approval of a new indication...
Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease
China-based Sino Biopharmaceutical Limited (HKG: 1177) announced that its self-developed JAK/ROCK dual small molecule inhibitor,...
Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...
BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...
Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received breakthrough devices...
Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline
According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS)...
Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation
On August 6, 2025, seven Shanghai-based authorities jointly issued a notice titled “Several Measures on...
Hengrui’s Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that it has received...
Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales
US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY)...
Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first...
Qyuns Therapeutics’ QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19...
Sino Biopharmaceutical’s TQC3302 Approved for COPD Maintenance Treatment Clinical Trials
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug,...